CYP3A4抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Western blot analysis using CYP3A4 mouse mAb against Rat liver cell lysate.    

  
  

•  

   

     Immunofluorescence analysis of HepG2 cells using CYP3A4 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.    

  
  

•  

   

     Flow cytometric analysis of HepG2 cells using CYP3A4 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human liver cancer tissues using CYP3A4 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human brain tissues using CYP3A4 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded Mouse liver using CYP3A4 mouse mAb with DAB staining.    

  
  

The cytochrome P450 3A4 (CYP3A4) enzyme, a member of the CYP450 superfamily, is a critical catalyst in the metabolism of xenobiotics, including approximately 50% of clinically used drugs. It is predominantly expressed in the liver and intestines, where it facilitates phase I oxidation reactions to enhance drug elimination. CYP3A4 antibodies are essential tools for studying the enzyme's expression, regulation, and activity in both physiological and pathological contexts. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to quantify CYP3A4 protein levels, assess tissue distribution, or investigate interactions with drugs or endogenous compounds.

Research using CYP3A4 antibodies has highlighted its role in drug-drug interactions (DDIs), genetic variability, and disease-related expression changes. For instance, polymorphisms or drug-induced modulation of CYP3A4 can alter drug efficacy or toxicity, impacting personalized medicine strategies. Additionally, CYP3A4 antibodies aid in studying hepatic diseases, cancer (where CYP3A4 may influence chemotherapy metabolism), and regulatory mechanisms involving nuclear receptors like PXR or CAR.

Both monoclonal and polyclonal CYP3A4 antibodies are available, with specificity validated using recombinant proteins or tissue samples. Their applications extend to drug development pipelines, toxicology assessments, and biomarker discovery, underscoring their importance in pharmacology and biomedical research.